Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Upstream Bio, Inc.NASDAQ: UPB

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $3.02M fell 36.2% year over year, behind the -2.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 18.4% from the prior quarter. Over 3 fiscal years it compounded at +644.5% a year.

Context

  • Other income / expenses amounted to 592.8% of revenue in FY2025, down 38.4 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -36.2% toward the trailing-twelve-month pace of -2.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.02M-18.4% QoQ
Last fiscal yearDec 2025
$16.92M+13.1% YoY
LTMMar 2026
$15.2M-2.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.2%——
1 year+13.1%——
3-year CAGR+644.5%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
16.92M USD
Year-over-year change
+13.1%
3-year CAGR
+644.5%

Other Income / Expenses vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.5% is the 5th highest of 10, against a peer median of -22.6%.
  • Other income / expenses amounts to 457.5% of revenue for UPB, versus a peer median of 16.8%.
UPB Competitors
Other Income / Expenses for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$26.12M USD+72.4%—39.5%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$24.4M USD-22.6%+44.2%235.7%
UPBUpstream Bio, Inc.LTM Mar 2026$15.2M USD-2.5%+644.5%457.5%
PHVSPharvaris N.V.LTM Sep 2026€14.39M EUR+118.3%——
WVEWave Life Sciences Ltd.LTM Mar 2026$13.29M USD-1.0%+91.1%18.5%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$12.59M USD+69.5%+32.0%—
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$1.95M USD-117.5%——
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$13.69M USD-121.2%+303.0%15.1%
NVAXNovavax, Inc.LTM Mar 2026-$19.43M USD-125.2%—3.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-$19.72M USD-255.1%—9.1%
Peer median (excluding UPB) —-22.6%+67.6%16.8%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.